| Institution: | 1.Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy,Nanjing University of Chinese Medicine,Nanjing,China;2.Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine Prevention and Treatment of Tumor,Nanjing University of Chinese Medicine,Nanjing,China;3.Department of Pharmacy,Provincial Hospital Affiliated to Anhui Medical University,Hefei,China;4.Fujian Provincial Hospital,Clinical College of Fujian Medical University,Fuzhou,China;5.Department of Pharmacology, Hanlin College,Nanjing University of Chinese Medicine,Taizhou Jiangsu Province,China;6.Department of Pharmaceutics, Jinling Hospital,Nanjing University School of Medicine,Nanjing,China |
| Abstract: | Accumulative evidences have underpinned the nature candidates from Chinese medicine (CM), particularly CM served as blood activating and stasis resolving (BASR, Huoxue Huayu in Chinese) by targeting tumor-associated angiogenesis. However, recent experiment research on the therapeutic angiogenesis by BASR-CM attracts wide attention and discussion. This opinion review focused on the underlying link between two indications and anticipated that (1) BASR-CM might emphasize on a balanced multi-cytokines network interaction; (2) BASR-CM might address on the nature of diseases prior to differently affecting physiological and pathological angiogenesis; (3) BASR-CM might mainly act on perivascular cells, either promotes arteriogenesis by increasing arteriogenic factors in ischemic diseases, or simultaneously keep a quiescent vasculature to impede angiogenesis in tumor context. |
